New Trials in Gynecologic Cancers
-
Several new clinical trials investigating novel drugs in gynecologic cancers have opened in recent months. Maybe one of your patients could benefit from taking part. Patients who have received one of these diagnoses and have run out of appropriate treatment options can join a phase 2, open-label study testing the experimental checkpoint inhibitor vudalimab (XmAb20717, developed by Xencor). This clinical trial has two stages. In the first stage, 10 people with each type of cancer will receive vudalimab by intravenous (IV) infusion every 2 weeks. If at least two patients with a particular diagnosis respond within 12 weeks, researchers will enroll 20 more people into that group. If fewer than two people respond, no more patients will be enrolled for that cancer type. The sole outcome measure is objective response rate (ORR) over 12 weeks. Overall survival (OS) and quality of life (QoL) will not be tracked. Sites in California, Nevada, and New York started recruiting in July 2022. The goal is to enroll 150 participants.
-
@uller This is an interesting study examining the potential utility in gynecologic malignancies of a novel bispecific antibody targeting two relevant immune checkpoints